The liver regulates essential metabolic functions, detoxification pathways, and systemic homeostasis critical for survival. CELLnTEC provides precision in vitro cell culture systems to advance hepatology research, translational liver biology, and regenerative medicine. Through strategic collaboration in initiatives such as the NEOLIVER consortium, we help translate cutting-edge liver science into clinically relevant therapies, transplantable tissues, and next-generation ATMPs in hepatology.
CELLnTEC drives the standardization and optimization of patient-derived cell expansion within the framework of the NEOLIVER project, a pioneering European initiative. This technological foundation is indispensable for scaling the production of consistent, high-quality bioprinted tissues suitable for therapeutic interventions. CELLnTEC plays a pivotal role in the NEOLIVER project by applying its expertise in fully defined, animal and human component-free precision cell culture technologies.
Liver diseases including NAFLD, NASH, fibrosis, cirrhosis, and liver cancer affect millions worldwide and often progress silently to advanced stages. Limited donor organs and rising chronic disease incidence demand improved in vitro models, predictive diagnostics, and scalable regenerative solutions. Advanced 3D liver models and human liver tissue systems are critical to reduce clinical translation failure and enhance therapeutic development.
We support expansion of liver organoids and supporting cells, refinement of co-culture conditions, and implementation of vascularization strategies for robust 3D liver tissue engineering. Our controlled, reproducible culture systems enhance tissue maturity, hepatic function, and long-term stability. These physiologically relevant platforms enable disease modeling, drug development, toxicity screening, and preclinical workflows.
As part of the European Union–funded NEOLIVER consortium, we contribute to automated processes for generating dense, perfusable, functional bioprinted liver constructs. These engineered tissues are designed for scalable production, standardization, and stringent quality control—core requirements for regenerative hepatology and future clinical application of advanced therapy medicinal products (ATMPs).
By integrating liver biology with automation, translational manufacturing, and advanced biomanufacturing strategies, we will support the development of clinically aligned engineered tissues in the future. We are working on optimizing vascularized constructs, organoid-based platforms, bioprinted liver systems to accelerate innovation toward solutions for liver failure and chronic liver disease.
Primary epithelial cells growing in CnT-NX-EX display a highly proliferative phenotype. For differentiation experiments, it is recommended to switch to the CnT-PR-D or CnT-PR-3D differentiation media.
